Lovidia™ “Drug-like efficacy and food-like safety" in supplement form for weight management
Lovidia is a proprietary mix of Generally Recognized As Safe (GRAS)-designated dietary ingredients and FDA-approved food additives, targeted to the consumer market as an over-the-counter product. Lovidia can be used for multiple applications including as a dietary supplement for weight management, and as a food additive for satiety and lower glycemic index.
Our first-generation Lovidia product demonstrated statistically significant, progressive and sustained weight loss in a randomized, placebo-controlled, double-blinded clinical study. A threefold higher proportion of subjects lost 3 to 5 percent of their body weight compared to placebo in a 16-week study evaluating 121 obese subjects. This was accomplished without diet or exercise modification. The tolerability and safety profile was similar to placebo. Lovidia increased the body’s food-driven production of natural satiety and gluco-regulatory gut hormones twofold; with the same number of calories, subjects had twice the satiety signals. In 2013 Elcelyx plans to conduct a 200-subject efficacy trial with a second-generation optimized form of Lovidia and to prepare for commercialization in early 2014.
Sixty percent of the adult U.S. population is overweight and 30 percent are classified as obese based on body mass index (BMI)2. Inadequate weight management can have physical, medical and social implications. There are few FDA-approved treatments for weight loss and their use is expected to be limited due to modest efficacy coupled with potential side effects. Although there are several over-the-counter products with weight loss claims, these agents often lack meaningful efficacy. There is a tremendous unmet need for safe, efficacious and convenient weight loss supplements to support health and overall well being.
The biology underlying food intake and, in particular, meal cessation involves a number of hormonal and neural signals emanating from the gut which, in turn, communicate to the brain a sense of fullness and signal us to stop eating. Diabetes and obesity are associated with a weakened satiety-signaling pathway. Therefore, approaches that strengthen or restore normal physiology are highly desirable.
2WIN, Weight-control Information Network, NIDDK